Abstract | The discovery that cancer can be governed above and beyond the level of our DNA presents a new era for designing therapies that reverse the epigenetic state of a tumour cell. Understanding how altered chromatin dynamics leads to malignancy is essential for controlling tumour cells while sparing normal cells. Polycomb and trithorax group proteins are evolutionarily conserved and maintain chromatin in the 'off' or 'on' states, thereby preventing or promoting gene expression, respectively. Recent work highlights the dynamic interplay between these opposing classes of proteins, providing new avenues for understanding how these epigenetic regulators function in tumorigenesis.
Tumours are composed of diverse cell types, some of which contribute to resistance to anticancer therapy, tumour relapse and metastasis. Models explaining tumour heterogeneity include the cancer stem cell hypothesis and the clonal evolution model [1] [2] [3] . Regardless of which model is favoured, the ultimate goal of cancer therapeutics is to target the cells that lead to tumour recurrence -the tumour-propagating cells. Developmental pathways are often inappropriately reactivated in cancer cells, suggesting that tumour-propagating cells have hijacked cellular networks that control the behaviour of normal stem cells, empowering them with enhanced proliferative potential 4, 5 . In some cancers, such as acute myelogenous leukaemia (AML), renewal capacity relies on a transcriptional programme that is active in embryonic stem cells (rather than adult stem cells) 6 . Therefore, striking parallels between mechanisms orchestrating normal embryogenesis and those that modulate tumorigenesis could be exploited to treat cancer.
Development of an embryo requires cell fate decisions to establish the lineage of a cell, as well as a system for 'remembering' this identity throughout subsequent rounds of cell division. How this cellular memory is maintained during the life of an organism is a fundamental question in development. This also impinges on our understanding of cancer, as the cellular memory system that normally governs cell behaviour goes awry in cells within a tumour, which cripples the activity of tumour suppressors and spuriously activates proto-oncogenes, endowing cells with relentless proliferative capacity and loss of cell identity.
An understanding of the mechanistic basis of cellular memory began in 1978 when P. Lewis and E. Lewis described a series of Drosophila melanogaster mutants called Polycomb (Pc) (FIG. 1) . Specific body segments of these mutants had the identity of a completely different, but otherwise normal, body segment. Although transcription factors had initially established the proper identity of cells within the region of the embryo that would eventually give rise to the adult segment, cells of Pc mutants failed to transmit this information to daughter cells, producing remarkable phenotypes such as adult animals with legs in the place of antennas [7] [8] [9] . Pc mutations caused inappropriate reactivation of genes that should have been repressed, such as homeotic genes that dictate segment identity, causing a specific body segment to take on an entirely new character. This failure in the cellular or transcriptional memory system led to the idea that polycomb group (PcG) proteins repress gene expression by keeping chromatin in a transcriptionally inactive or 'off ' state [10] [11] [12] [13] [14] 
.
Subsequent genetic screens in D. melanogaster identified a second category of proteins, the trithorax group (TrxG) proteins, which counteract the action of PcG proteins FIG. 1 ). This indicated that TrxG proteins function as 'anti-silencers' to activate the expression of homeotic genes 8, 15, 16 . Therefore, PcG and TrxG proteins work together to regulate chromatin dynamics and gene expression cascades to retain cellular memory throughout the life of the organism 17 . Not only is this PcG-TrxG-regulated cellular memory system evolutionarily conserved, an imbalance in this system in Cancer stem cell hypothesis
The theory that tumours are composed of a heterogeneous population of cells, including a subset of relatively rare cancer stem cells or 'tumourpropagating' cells that are essential for malignancy.
Clonal evolution model
The theory that tumourpropagating cells make up a considerable proportion of cells in a tumour, and that the malignant state is the consequence of the selection of dominant clones in the population.
Histone code
The concept that the establishment and interpretation of an intricate pattern of histone tail modifications orchestrate chromatin dynamics and gene expression. mammals has also been associated with compromised stem cell renewal, as well as with an increased risk of cancer (FIG. 1b,c) . Genetic lesions that cause inappropriate PcG and TrxG activity -such as alterations in expression level, mutational activation or inactivation, as well as chromosomal deletion, amplification or translocation -predispose to cancer (TABLE 1) . Anticancer therapies aimed at reversing perturbations in the PcG-TrxG cellular memory system have shown considerable promise in the clinic 18 . This Review focuses on recent advances in understanding how PcG-TrxG-mediated chromatin dynamics converge to regulate tumorigenesis.
PcG and TrxG regulate chromatin dynamics
Histone modification. Covalent modification of specific residues within amino-terminal tails of histones alters chromatin structure and function; the unique combination of modifications has been described as the histone code. Both PcG and TrxG proteins affect histone methylation, for example, but these opposing classes of proteins methylate distinct residues, resulting in different biological outcomes. PcG proteins establish histone modifications that repress transcription, whereas TrxG proteins establish histone modifications that activate transcription
There are two core PcG complexes, each of which is made up of multiple subunits (FIG. 2a; TABLE 1 ). Polycomb repressive complex 2 (PRC2) establishes the histone code, and PRC1 interprets this code 19 . The mammalian PRC2 complex contains enhancer of zeste homologue 2 (EZH2), embryonic ectoderm development (EED), suppressor of zeste homologue 12 (SUZ12) and retinoblastoma-binding protein 4 (RBBP4) or RBBP7 (REF. 20 ). EZH2 contains a SET domain and is a histone methyltransferase (HMT) that trimethylates histone H3 at lysine 27, which is characteristic of inactive chromatin 21 . Although PRC2 had also been reported to establish the H3K9me3 repressive mark 22 , this has remained controversial. EED and SUZ12 do not possess HMT activity, but these subunits are required for the HMT activity of EZH2 (REF. 23 ). In D. melanogaster, PRC2 binds polycomb repressive elements (PREs) throughout the genome. PREs in mammals have been more difficult to identify, although PREs within the mafb and Hox loci were recently functionally characterized 24, 25 . H3K27me3, but not H3K9me3, is lost in PcG mutants, highlighting the importance of H3K27me3 in maintaining cellular memory.
The repressive histone marks established by PRC2 are recognized by PRC1, which stabilizes the inactive state so that transcriptional memory is maintained. There are multiple forms of mammalian PRC1 complexes, which can contain chromobox homologue 2 (CBX2), CBX4 or CBX8, polyhomeotic homologue 1 (PHC1), PHC2 or PHC3, BMI1, and ring finger protein 1 (RING1) or ring finger protein 2 (RNF2) 26 (FIG. 2a; TABLE 1) . CBX proteins contain a chromatin organization modifier domain (chromodomain), which recognizes and binds the H3K27me3 mark established by PRC2. BMI1, RING1 and RNF2 have RING finger domains, motifs that are crucial for nuclear localization as well as for the oncogenic activity of BMI1 (discussed below) 27 . A working model for how PcG complexes modulate chromatin is that transcription factors and their associated machinery dictate loci destined for silencing, and PRC2 tags these target loci by methylating lysine 27 of histone H3. This H3K27me3 mark is recognized and bound by the chromodomain of CBX2, CBX4 or CBX8 within PRC1, which mediates transcriptional silencing by binding methylated histones in the vicinity and ubiquitylating histone H2A 28, 29 . Although in vitro assays have suggested that PRC complexes mediate silencing by physically blocking the binding of transcriptional machinery at promoters 30 , PRC complexes are more likely to function by impeding RNA polymerase II (RNA Pol II) initiation or elongation. Indeed, several groups have shown that RNA Pol II and basal transcription factors are present at PcG-silenced loci [31] [32] [33] . Although the hierarchical recruitment model in which PRC2 and PRC1 bind sequentially is attractive, recent evidence indicates that PRC2 and PRC1 bind some loci simultaneously, and that not all PRC2-bound loci are bound by PRC1 (REF. 34 ). Furthermore, PRC1 can bind chromatin in the absence of PRC2 (REFS 35, 36) .
Similar to PcGs, TrxG proteins are also components of multisubunit complexes, although their composition is not as well characterized. TrxG proteins can, however, be broadly classified into two categories: the histone modifiers 37 and the nucleosome remodellers 
At a glance
• Transcriptional programmes established during embryogenesis are transmitted to daughter cells of the adult so that each cell maintains its appropriate identity, a process referred to as cellular or transcriptional memory. Loss of cellular memory can lead to the spurious transcription of oncogenes and silencing of tumour suppressors, which predisposes to cancer.
• Polycomb group (PcG) and trithorax group (TrxG) proteins affect covalent modifications of histone tails, the position or composition of nucleosomes, as well as DNA methylation, thereby affecting chromatin structure and so transcriptional status. In general, PcG proteins repress -whereas TrxG proteins activate -gene expression.
• Gain of PcG and loss of TrxG function occurs in various human cancers, which is consistent with the idea that tumour cells have stem-like characteristics. This concept is supported by the observation that tumour cells have gene expression profiles that are similar to that of embryonic cells.
• The balance between PcG and TrxG proteins affects the expression of genes that induce cellular senescence -a tumour suppressive mechanism that opposes cellular proliferation.
• PcG-TrxG-mediated chromatin dynamics affects the expression of genes that regulate apoptosis, a process that controls unscheduled cellular proliferation by inducing cell death. PcG proteins can recruit proteins that transcriptionally silence genes encoding components of the apoptotic machinery.
• PcG-TrxG complexes function to maintain the integrity of the genome. The observation that loss of TrxG chromatin remodelling proteins predispose to cancer, even in the absence of genomic lesions, implies that modulation of PcG-TrxG function can be used to treat cancer. Nature Reviews | Cancer However, in contrast to EZH2, which methylates histone H3 at lysine 27 to establish a repressive histone mark, TrxG HMTs methylate histone H3 at lysine 4 to establish active chromatin marks 39 (FIGS 2,3a). The human TRX homologue mixed-lineage leukaemia (MLL) occupies the promoters of Hox genes, facilitating H3K4 methylation and transcriptional activation 40 . Therefore, both PcG and TrxG complexes regulate chromatin by directly methylating histones.
In addition to methylation, PcG and TrxG complexes either directly or indirectly recruit proteins that facilitate other covalent histone modifications, such as acetylation (FIG. 3b) . Histone acetylation status is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation of histones near promoters is associated with transcriptional activation; therefore, HATs and HDACs favour transcriptional activation and repression, respectively. PcG and TrxG complexes recruit these enzymes (FIG. 3b) . For example, the HDACs sirtuin 1 (SIRT1) and HDAC2 have been purified in PRC complexes 20 . By contrast, the HAT MYST1 (which acetylates H4K16, a mark of actively transcribed genes) has been purified in MLL-containing complexes 41 . Although ASH1 complexes are not fully characterized, it is known that ASH1 interacts with the HAT CREBbinding protein (CBP; also known as CREBBP), which is a transcriptional co-activator 42 . Importantly, acetylation prevents the establishment of H3K27me3. Therefore, TrxG proteins facilitate transcriptional activation by establishing activating histone methylation and acetylation marks, while simultaneously preventing PcG complexes from depositing inactivating histone methylation marks. These complexes link histone methylation and histone acetylation. PcG and TrxG complexes can also 
SWI2-SNF2
A complex identified in yeast that is required for transcriptional activation of ~7% of the genome, including the mating type switch (SWI) and the sucrose nonfermenting (SNF) genes for which SWI2-SNF2 are named.
recruit histone demethylases (HDMs), indicating that the reversal of PcG-and TrxG-mediated histone methylation regulates chromatin dynamics and transcription (FIG. 3c) . In addition, PcG complexes can recruit DNA methyltransferases (DNMTs) (FIG. 3d) , indicating that the repressive methylation of histones is linked to the methylation of DNA -a mechanism by which tumour suppressor genes can be inactivated in human cancer (discussed below). PcG-TrxG not only regulates transcriptional on and off states, but it is also an adaptable system that allows for graded responses between these extremes. In this dynamic fashion, the bivalent chromatin state of pluripotent embryonic stem cells in which both activating and repressive histone marks are present 43 can be fine-tuned as differentiation proceeds, as was shown in cells of the ectodermal lineage 44 . Therefore, although PcG and TrxG proteins can directly methylate histones, they are also able to recruit additional proteins that greatly expand their repertoire of covalent histone and DNA modifying activities. The observation that S. cerevisiae SWI2-SNF2 mutant phenotypes are repressed by mutations in nuclear histones firmly established a functional connection between SWI2-SNF2 and nucleosomes 48, 49 . Subsequent work revealed that SWI2-SNF2 complexes consist of multiple subunits and modulate nucleosome position and/or composition.
ATP-dependent chromatin remodelling enzymes contain ATPase subunits belonging to the SNF2 superfamily; the sequence of the ATPase domain further subdivides this superfamily 50 . Mammalian SNF2 families are also characterized by domains homologous to D. melanogaster proteins: SWI-SNF subunits have a
Box 1 | Chromatin dynamics regulate transcriptional memory and cancer
Chromatin structure is regulated by polycomb group (PcG) and trithorax group (TrxG) complexes that keep chromatin in an 'off' (see the figure; left) or 'on' (see the figure; right) state, respectively, thereby regulating proteins controlling transcription, DNA replication and DNA repair. Chromatin has a fundamental role in regulating biological processes that are commonly perturbed in cancer. Alterations in the expression of proteins regulating chromatin structure, and consequent changes to the specific chromatin marks they create, have been extensively documented in human cancer 18, [132] [133] [134] . An imbalance in chromatin dynamics can lead to cancer by inactivating tumour suppressors, activating oncogenes, or by reactivating pathways that inhibit differentiation or favour stem cell self-renewal. The three general strategies outlined below, histone modification, DNA methylation and nucleosome remodelling, work together to regulate chromatin structure and to maintain cellular memory, regulating processes that frequently go awry in cancer.
Covalent modification of histones
Amino-terminal histone tails protruding from nucleosomes can be modified at specific residues through methylation, acetylation, phosphorylation, ubiquitylation, sumoylation and ADP-ribosylation. These modifications are likely to affect the ability of chromatin readers to recognize and bind to local nucleosomes. Enzymes that covalently modify histone residues include histone methyltransferases (HMTs) that establish the H3K27me3 mark characteristic of repressed genes (see the figure; left), as well as HMTs that establish the H3K4me3 and H3K36me3 marks characteristic of actively transcribed genes (see the figure; right). Histone demethylases (HDMs) remove these marks. Histone acetylases (HATs) acetylate histone tails, whereas histone deacetylases (HDACs) remove these acetyl groups. Acetylation of histones is a characteristic of the promoters of actively transcribed genes; therefore HDACs and HATs inhibit and activate gene expression, respectively.
DNA methylation
DNA is methylated at CpG dinucleotides by DNA methyltransferases (DNMTs). DNA hypomethylation was the first epigenetic change to be reported in human cancer, leading to enhanced genomic instability. By contrast, hypermethylation of CpG islands located near promoters causes silencing of tumour suppressor genes such as hypermethylated in cancer 1 (HIC1), CDKN2A, CDKN2B, mutL homologue 1 (MLH1), Ras association domain family member 1 (RASSF1) and von Hippel-Lindau tumour suppressor (VHL) 135 .
Nucleosome remodelers ATP-dependent chromatin remodelling complexes use the energy obtained from ATP hydrolysis to alter the positioning, conformation and/or composition of nucleosomes, serving as chromatin remodelling engines. Nucleosome dynamics has a dramatic effect on chromatin structure, with nucleosome-free regions associated with actively transcribed genes. , neuroblastoma [166] [167] [168] [169] [170] [171] , meninigioma 172 , melanoma 173 , pheochromocytoma [174] [175] [176] [177] , oligodendroglioma [178] [179] [180] 
PHD finger
Around 50-80 residues containing the Cys 4 -His-Cys 3 motif originally identified in Arabidopsis thaliana that binds specifically modified histones.
bromodomain that is related to BRM, ISWI subunits have a SANT domain that is related to ISWI, and the chromodomain helicase DNA binding (CHD) family is characterized by chromodomains that are related to CHD1, Mi-2 and Kismet (KIS) (TABLE 1) . Mammalian ATP-dependent nucleosome remodelling proteins enhance gene expression by facilitating transcriptional elongation by RNA Pol II 51 . Although nucleosome remodelling proteins were first associated with transcriptional activation, these complexes can also function as transcriptional repressors 52 (FIG. 3e) . Models proposed for the mechanism by which nucleosome remodelling proteins affect gene expression include chromatin looping, nucleosome sliding, nucleosome eviction and exchange of variant histones; these events facilitate the binding of transcription factors 53 and basal transcription machinery 54 . The histone modifying and the nucleosome remodelling classes of TrxG proteins are not mutually exclusive: TrxG proteins that are HMTs can recruit nucleosome remodelling TrxG proteins. For example, MLL has been purified from a complex containing WD repeat domain 5 (WDR5), a plant homeodomain finger (PHD finger)-containing protein required for H3K4me3 that recruits the nucleosome remodelling factor (NURF) complex, indicating that H3K4me3-mediated transcriptional activation is associated with nucleosome remodelling 55 . Therefore, the interplay between PcG and TrxG complexes integrate histone modifications, DNA methylation and nucleosome remodelling, which affects chromatin structure and gene expression in a complex and dynamic fashion. The varied composition of the complexes might reflect dynamic changes during development or within tissue-specific contexts, adding further diversity to the PcG-TrxG-regulated cellular memory system.
PcG-TrxG-mediated regulation of tumorigenesis
The gain of PcG and loss of TrxG is a common theme in human cancer, demonstrating the oncogenic and tumour suppressive roles, respectively, of these complexes (FIG. 1c;  TABLE 1 ). For example, BMI1 is an oncogene 56, 57 , whereas CHD5 is a tumour suppressor 58 . However, perturbations of other TrxG proteins, such as MLL, cause malignancy through gain-of-function mechanisms. Mechanisms leading to the deregulation of PcG proteins in cancer highlight the role of the cell fate transcription factors and long noncoding RNAs, as recently reviewed 14 . Many tumours have reactivated expression of stem cell-associated genes, such as Hox genes, which are the best characterized targets of PcG and TrxG proteins, and this is consistent with the idea that cellular memory is compromised. PcG and TrxG complexes function reciprocally to regulate transcriptional programmes that affect senescence, the cell cycle, apoptosis and genomic stability. Cellular senescence. BMI1 was the first PcG protein to be implicated in cancer. It was initially identified as an oncogene that cooperates with MYC in lymphomagenesis 56, 57 , and subsequent studies found it robustly expressed in human cancers (TABLE 1) . BMI1 facilitates tumorigenesis by mediating escape from cellular senescence, which is a state of withdrawal from the cell cycle that provides a potent tumour suppressive mechanism in vivo 59 . The mechanism whereby BMI1 promotes evasion of senescence involves transcriptional silencing of the cyclin-dependent kinase inhibitor 2A (CDKN2A, which encodes both p16 INK4A and p14
ARF
) and CDKN2B (which encodes p15
INK4B
) loci, mapping to human chromosome 9p21 (REFS 20, 60) . Silencing of CDKN2A and CDKN2B simultaneously shuts down expression of three tumour suppressors 61, 62 (FIG. 4a) . INK4A (also known as p16) and INK4B (also known as p15) are cyclin-dependent kinase inhibitors (CKIs) that prevent CDK4-dependent phosphorylation of retinoblastoma (RB), thereby preventing E2F-mediated cell cycle progression. BMI1 coordinately represses CDKN2A and CDKN2B loci by mediating the loading of CDC6 onto a cis-acting replication origin several thousand nucleotides upstream of the transcriptional start site 63 . This was the first example of a replication-coupled transcriptional repression mechanism in mammals. Repression of CDKN2A and CDKN2B loci is a recurring theme in tumorigenesis: mouse models with deletions of these loci are tumour prone, and they are frequently inactivated in human cancers by deletion, mutation or DNA hypermethylation 64 . Senescence limits proliferation, so proliferating cells must inhibit senescence to maintain proliferative potential; PcG-mediated transcriptional repression of CDKN2A has a pivotal role in inhibiting senescence 65 (FIG. 4b) . The renewal capacity of both neural and haematopoietic stem cells was dramatically compromised in Bmi1 -/-mice 66, 67 , which occurred concomitantly with homeotic phenotypes such as the second cervical vertebrae possessing the identity of the third cervical vertebrae, which is reminiscent of the loss of cellular memory that is observed in D. melanogaster PcG mutants 68 (FIG. 1b) . These phenotypes are partially rescued by depletion of p16
INK4A
, underscoring the crucial role of BMI1-mediated repression of this senescence inducer. Renewal capacity is also maintained in mouse embryo fibroblasts (MEFs) through PcG-mediated repression. Activated oncogenes such as HRAS or BRAF -which induce the senescence of proliferating MEFsresult in reversal of PcG-mediated repression of p16
(REFS 69,70). Oncogene-induced senescence coincides with the loss of PcG protein (for example, EZH2, SUZ12, BMI1 and CBX8) binding at the CDKN2A and CDKN2B loci, as well as the transcriptional repression of EZH2, and coincident transcriptional activation and recruitment of the H3K27me3 HDM, jumonji domain-containing 3 (JMJD3; also known as lysine-specific demethylase 6 (KDM6B)). The repressive H3K27me3 marks are replaced with activating ones (H3K4me3), RNA Pol II is recruited and p16
INK4A expression is induced, culminating in senescence. The presence of AP1 consensus binding sites in the JMJD3 promoter suggests that this transcription factor has a role in BRAF-mediated transcriptional activation of JMJD3 (REF. 70 ). This indicates that the ability of normal primary cells to resist oncogene-mediated transformation depends on a switch between PcG-mediated repression and TrxG-mediated activation.
PcG-mediated repression is also reversible in cancer cells, as TrxG proteins can override PcG-mediated repression, leading to the reactivation of tumour suppressors. SWI-SNF chromatin remodelling complexes contain an ATPase subunit (either BRM or BRG1) as well as the non-catalytic subunit (SNF5) that is common to various SWI-SNF-like complexes 71, 72 (FIG. 2) . Loss of SNF5, BRM or BRG1 has also been associated with human cancer (TABLE 1) . Malignant rhabdoid tumours (MRTs) -a rare but extremely aggressive form of childhood cancer -are caused by biallelic deletion or truncating mutations of SMARCB1 (which encodes SNF5).
Reintroduction of SNF5 into human MRT cells (which are deficient for this non-catalytic subunit of SWI-SNF) can alleviate PcG-mediated repression and reverses the (FIG. 4c) . Expression of SNF5 in MRT cells induces cell cycle arrest and senescence 74, 75 , increasing the expression of p16 INK4A , increasing hypophosphorylated RB and compromising expression of E2F target genes 76, 77 . SNF5 recruits the catalytic BRG1 subunit to the CDKN2A and CDKN2B promoters, facilitating the binding of RNA Pol II. SNF5-mediated recruitment of BRG1 coincides with the removal of PRC1 and PRC2 repressive complexes, as well as the dissociation of DNMT3B and consequent decreased DNA methylation 73 . MLL is simultaneously recruited, repressive histone marks are then replaced with active ones and senescence is induced. SNF5-mediated senescence requires the ATPase activity of BRG1. This demonstrates that, contrary to previous reports obtained in vitro 78 , SWI-SNF activity can override PcG-mediated silencing, exemplifying the dynamic interplay between the PcG and TrxG complexes.
The studies in MRT cells showed that SNF5 induces senescence by activating p16
-RB-mediated pathways. Although Smarcb1 +/-mice develop spontaneous MRTs of the brain [79] [80] [81] , tumorigenesis was not increased in either Rb1-or Cdkn2a
-deficient backgrounds 82, 83 . Similarly, although Smarca4 +/-(which encodes BRG1) mice develop mammary gland carcinomas 84 , tumorigenesis was not increased in an Rb1 +/-background 85 . Although these findings implicate SWI-SNF proteins in tumour suppression in vivo, they do not support the findings that p16
-RB-mediated pathways are also involved. By contrast, evidence for a genetic connection between SNF5-and RB-regulated pathways was obtained when it was found that the inactivation of cyclin D1 inhibits tumorigenesis of Smarcb1 +/-mice, thus placing cyclin D1 downstream of SNF5 (REF. 86 ). To determine whether SWI-SNF complexes inhibit tumorigenesis through RB-related proteins, tumour incidence was monitored in Smarcb1 +/-mice that also carried the T121 transgene, which is a truncated version of simian virus 40 (SV40) T-antigen that inhibits each of the three Rb family pocket proteins (RB, p107 and p130) 85 . Mice expressing the T121 transgene under the control of the lymphotrophic papovavirus (LPV) promoter develop -RB-and ARF-p53-mediated tumour suppression. Based on findings from REF. 73 . P, phosphorylation; RB, retinoblastoma.
Chromosome engineering
A Cre-loxP-based embryonic stem cell technology that enables the generation of mouse models harbouring defined chromosome rearrangements such as deletions, duplications, inversions and translocations.
choroid plexus carcinomas (CPCs), a tumour type that also develops in patients with inactivating mutations in SMARCB1. Although CPC development is not enhanced in Smarcb1 +/-;LPV-T121 mice and the wild-type Smarcb1 locus was retained, these mice develop MRTs with increased penetrance and decreased latency. Therefore, SNF5 and Rb family members cooperate to suppress cancer in a cell type that leads to MRTs, but not in a cell type that leads to CPCs 85 . TrxG proteins of the nucleosome remodelling class also regulate senescence by transcriptional modulation of CDKN2A. CHD5 was shown to be a tumour suppressor that regulates expression of p16 INK4A and p19 ARF (the mouse homologue of p14 ARF ) 58 . Mammalian CHD proteins are homologues of the D. melanogaster TrxG proteins Mi-2 and KIS, and on the basis of structural homology to these TrxG proteins, CHD5 is thought to function as a nucleosome remodeller 87 . CHD3 and CHD4 (the CHD proteins that are most similar to CHD5) are homologues of D. melanogaster Mi-2α and Mi-2β, respectively; these proteins define the nucleosome remodelling and histone deacetylation (NURD) complex. The function of CHD5 in cancer is striking. Compromised CHD5 -by either heterozygous deletion of the region of the chromosome encompassing Chd5 using chromosome engineering or specific depletion of Chd5 in MEFs using RNA interference -reduces p16 INK4A and p19 ARF expression and enhances proliferation 58 . Whereas the expression of oncogenic Hras G12V in wild-type MEFs induces senescence and prevents tumour formation, HRAS-mediated senescence is bypassed in MEFs in which CHD5 has been knocked down, leading to robust tumour formation in vivo 58 . Conversely, gain of the chromosomal region encompassing Chd5 augments expression of p16 INK4A and p19 ARF , causing reduced proliferation and senescence in MEFs, as well as homeotic defects and stem cell depletion in vivo 58 (A.A.M., unpublished observations).
As was the case for Bmi1 -/-mice, phenotypes resulting from the gain of the chromosome region encompassing Chd5 were alleviated when levels of p16 INK4A and p19 ARF were reduced 58 . The reciprocal nature of the cancer, homeotic and stem cell phenotypes of mouse models with altered gene dosage of Chd5 with those of Bmi1 (REFS 58, 88) , support the idea that CHD5 and BMI1 have opposing roles in vivo (FIG. 1) . Recent work in D. melanogaster indicates that KIS counteracts PcG-mediated repression by recruiting TRX and ASH1 to chromatin, reversing the H3K27me3 repressive mark and facilitating transcriptional elongation by RNA Pol II 89 . Whether CHD5 functions to counteract PcG-mediated repression awaits further study. These observations provide yet another example of the dynamic interplay between PcG and TrxG proteins in cancer and underscore the crucial role that gene dosage has in this process.
Cell cycle. Although the findings discussed above indicate that TrxG proteins are tumour suppressors, the role of MLL in cancer is more complex. MLL interacts with several proteins, including PcGs (such as BMI1 and PHC2), TrxGs (such as SNF5 and WDR5) and their accessory proteins (such as RBBP5, HDACs, and the HAT p300/CBP). Therefore, translocations involving human chromosome 11q23 -the most frequent genetic lesion in leukaemia 90, 91 that results in MLL fusions -probably disrupt PcG-TrxGmediated chromatin dynamics. This idea is supported by the observation that MLL fusions lose the HMT domain but retain the PcG-interacting regions 92 . MLL is normally expressed in a cell cycle-dependent manner; it is dynamically regulated by SKP1-CUL1-F-box (SCF) SKP2 -and anaphase promoting complex (APC) CDC20 -mediated degradation, resulting in two peaks of expression that facilitate G1/S and G2/M cell cycle transitions 93 . In contrast to wild-type MLL, MLL fusions are insensitive to cell cyclecoupled degradation, resulting in the constitutive expression of MLL throughout the cell cycle and the inappropriate expression of target genes 94 . In addition to being tightly coupled with cell cycle transitions, MLL is cleaved by the endopeptidase taspase 1 (TASP1) to generate amino-and carboxy-terminal peptides that heterodimerize to form functional MLL [95] [96] [97] .
MLL is not cleaved in Tasp1
-/-MEFs, which compromises its HMT activity 98 . The HMT activity of MLL seems to be crucial for its ability to transactivate its targets, as MLL increases H3K4me3 and activates the transcription of E2F target genes that are required for cell cycle progression 99 . The co-regulator host cell factor C1 (HCF1) interacts with E2F1 and recruits MLL, thereby serving as a switch during the transition between G1 and S phase. Mature MLL transcriptionally modulates both cyclins and CKIs; in the absence of TASP1-mediated cleavage of MLL, expression of cyclin A, cyclin E and cyclin B is reduced, and p16
INK4A and p19 ARF are induced, which inhibits cell cycle progression 98 . Therefore, MLL is associated with the cell cycle on two different levels: it directly regulates the expression of key cell cycle regulators, and its level oscillates with cell cycle transitions.
The current view is that the oncogenic activity of MLL fusions is through a gain-of-function mechanism. Mlldeficient mouse models are inviable 100, 101 . Mll +/-mice are not tumour prone, but have aberrant expression of Hox genes and homeotic defects, such as cervical vertebrae with an identity that is inappropriate for that portion of the skeleton, which is reminiscent of the phenotypes observed in D. melanogaster. Conversely, leukaemia cells with MLL fusions have expression patterns that are typical of embryonic stem cells, consistent with the idea that cellular identity has been lost.
How can MLL fusions activate gene expression when the HMT-encoding C terminus is lacking? 90, 91, 102, 103 . Intriguingly, the MLL fusion partner AF10 (also known as MLLT10) interacts with DOT1-like histone H3 methyltransferase (DOT1L) 104 , a non-SET domaincontaining HMT that trimethylates H3K79, a mark of actively transcribed genes [105] [106] [107] . An artificial MLL-DOT1L fusion not known to occur in patients transforms myeloid cells in a manner similar to that of the tumour-derived MLL-AF10 fusion, and transformation activity is dependent on DOT1L-mediated H3K79me3 and enhanced HOXA9 expression 104 . The finding that MLL-DOT1L and MLL-AF10 fusions have similar transactivation activities suggested a model in which the MLL-AF10 fusion causes abnormal recruitment of DOT1L, changing H3K4me3 to H3K79me3 at specific target loci, including HOXA9 (REF. 104 ). DOT1L activity is required for both the establishment and maintenance of the transformed state in leukaemia cells with the MLL-AF10 fusion, suggesting that targeting this HMT might pose a new therapeutic strategy for leukaemias that are caused by this MLL fusion. It is possible that other MLL fusions are also capable of recruiting 'moonlighting' HMTs, an idea that requires further study.
Other MLL fusions can also recruit additional proteins that facilitate malignancy. The MLL fusion partner AF9 (also known as MLLT3) interacts with YEATs domain-containing 4 (YEATS4), a protein that is aberrantly upregulated in neuroblastoma 108 and is required for the repression of p53 (REF. 109 ). The ability of AF9 to recruit YEATS4 is retained in the MLL-AF9 fusion, providing a mechanism for aberrant inactivation of p53. The finding that YEATS4 can recruit SNF5, suggests that this MLL-AF9-YEATS4 triad promotes tumorigenesis by recruiting SWI-SNF complexes 110 . Aberrant recruitment of SWI-SNF complexes may also be a strategy used by the MLL-ENL fusion protein, as ENL (also known as MLLT1) has been purified from complexes that include SWI-SNF subunits 111 . In support of this model, MLL-ENL recruits SWI-SNF to the HOXA7 promoter, which results in the increased expression of HOXA7 -a protein that is essential for MLL-ENL-mediated oncogenesis 103 . MLL fusions have also been found in complexes containing JMJD3, suggesting that MLL fusions recruit machinery that removes repressive histone marks 112, 113 . These findings exemplify the different means by which leukaemogenic TrxG fusions exploit various components of the epigenetic machinery. Therefore, MLL fusions drive lymphomagenesis through a gain-of-function mechanism involving the misregulation of MLL during the cell cycle or the aberrant reactivation of specific developmental programmes through the opportunistic recruitment of PcG-TrxG-associated machinery.
Apoptosis. PcG-TrxG-mediated chromatin dynamics affects the expression of genes that induce apoptosis (FIG. 5a) . The general theme is that PcG proteins inhibit apoptosis, whereas TrxG proteins induce apoptosis. For example, the ability of PcG and TrxG proteins to work in opposing ways to regulate the CDKN2A locus (as discussed above) has a dramatic affect on p14 ARF expression. As an inhibitor of MDM2-mediated ubiquitylation and degradation of p53, p14 ARF 61 . Gain of PcG-mediated activity has the opposite effect: BMI1 cooperates with oncogenic HRAS in breast cancer cells by suppressing apoptosis and attenuating p53, p21 and caspase 3, leading to highly malignant tumours that metastasize to the brain 114 . BMI1 is essential for the survival and proliferation of both normal stem cells and leukaemia-propagating cells, and the depletion of BMI1 causes apoptosis, as well as senescence 115 . These findings underscore the role of PcG-mediated repression in modulating apoptosis through p19 ARF -mediated pathways. PcG proteins can also affect apoptosis by modulating the expression of genes other than CDKN2A ARF . PRC2-mediated recruitment of DNMTs can silence specific loci, such as those encoding the apoptotic machinery 116 . An 'apoptotic methylation signature' has been suggested as a strategy for diagnosing cancer 117 . EZH2 suppresses the expression of the apoptosis mediator DAB2-interacting protein (DAB2IP) in prostate cancer, thereby inhibiting tumour necrosis factor (TNF)-mediated apoptosis 118 . However, this repression is reversible, as HDAC inhibitors can induce apoptosis 119,120 -in some instances sensitizing tumour cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis 121 . The reversibility of this repression is underscored by the ability of the global histone methylation inhibitor 3-deazaneplanocin A (DZNep) to remove PRC2 components (such as EZH2, EED and SUZ12) from chromatin, reduce H3K27me3 and activate expression of the apoptosis effector F-box-only protein 32 (FBXO32) in breast cancer but not in normal cells 122 . TrxG proteins also modulate apoptosis. For example, the conditional inactivation of SNF5 in MEFs compromises cell survival and induces expression of p53 and p21, leading to apoptosis 82, 123 . Whereas p53 deficiency inhibited apoptosis of Snf5 -/-MEFs, p53 loss did not reverse their proliferation defect or rescue the embryonic lethality of Smarcb1 -/-mice 123 . However, tumour onset was extremely rapid when Smarcb1 and Trp53 were both inactivated using a Smarcb1 inverting conditional-Trp53 conditional-Mx-Cre model, presumably because apoptosis was suppressed 82 . CHD5 also regulates p53-mediated apoptosis. Whereas the loss of Chd5 compromises p53 activity and leads to tumorigenesis in vivo, the gain of Chd5 increases the senescence of MEFs in culture and triggers excessive apoptosis and perinatal lethality in vivo 58 . In contrast to the lethal apoptotic phenotype caused by SNF5 deficiency 123 , the apoptotic phenotypes caused by increased dosage of the region encompassing Chd5 were rescued in a p53-compromised background 58 . It remains to be determined whether p53 deficiency exacerbates tumorigenesis in mice with compromised CHD5.
In contrast to other TrxG proteins that induce apop tosis, some MLL fusions inhibit apoptosis 92 . This further supports the idea that MLL fusions work by a gain-of-function mechanism.
DNA damage responses and genomic integrity. SWI-SNF complexes suppress cancer by maintaining genomic integrity 77 (FIG. 5b) . Proliferation of human MRT cells could still be inhibited by the expression of a tumourderived SNF5 mutant, indicating that loss of cell cycle • Aneuploidy • Polyploidy control was not the only function of SNF5 responsible for tumorigenesis 124 . A subset of SNF5-deficient tumour cells grown in culture had multi-lobed nuclei and were polyploid or aneuploid, indicating that the mitotic checkpoint was defective 124 . Wild-type SNF5 inhibited the proliferation of these abnormal cells, thereby establishing a population of cells that were essentially all diploid. By contrast, the expression of tumourderived SNF5 mutants exacerbated genomic instability. Although wild-type SNF5 inhibited the proliferation of aneuploid cells, this was not the case when a version of CDK4 that could not be inhibited by p16
INK4A was simultaneously expressed, indicating that p16 INK4A -mediated pathways are essential for SNF5 to re-establish genomic integrity 124 . MEFs in which Smarcb1 was conditionally ablated were hypersensitive to DNA damage caused by cross-linking (induced by ultraviolet irradiation) and double-strand breaks (induced by doxorubicin) 123 . MEFs in which Smarcb1 was ablated had an altered nuclear structure and extra centrosomes, indicating that SNF5 deficiency leads to cytokinesis failure, polyploidy and genomic instability (FIG. 5b) . E2F1 and its downstream target MAD2 -the loss of which is associated with mitotic defects and aneuploidy 125 -were downregulated by SNF5 expression 124 . Furthermore, SWI-SNF complexes facilitate double-strand break repair by inducing phosphorylated H2AX (also known as γH2AX) at DNA lesions 126 . However, the results of a separate study in which the effects of Smarcb1 ablation were assessed at an earlier time point indicated that SNF5 loss does not cause hypersensivity to DNA damage and does not compromise the DNA damage checkpoint 127 ; this agrees with the finding that human MRT cell lines have a normal cell cycle checkpoint in response to DNA damage 128 .
In vivo evidence has also pointed to a role for SWI-SNF in regulating genomic stability. Mammary carcinomas of Smarca4 +/-mice are genomically unstable, but in contrast to MRT cells maintained in culture these tumours are not aneuploid 84 . Human MRTs as well as MRTs that develop in Smarcb1 +/-mice are diploid and genomically stable 127 . This implies that disruption of SWI-SNF-mediated chromatin remodelling activity can substitute for genomic instability in cancer. Therefore, perturbation of epigenetic events can contribute to cancer in the absence of genetic lesions 129 . These findings support the hypothesis that SWI-SNF proteins maintain genomic stability by coupling the cell cycle with DNA damage-induced checkpoints.
Conclusions and future perspectives
The mechanism whereby the PcG-TrxG-regulated cellular memory system goes awry during tumorigenesis is just beginning to emerge, unveiling the dynamic and complex nature of this epigenetic process. The ability to regulate cancer above and beyond the level of the DNA offers hope that cancer-causing perturbations can be reversed. Whereas classic tumour suppressors are lost or inactivated during tumorigenesis, several genes encoding TrxG proteins are retained. The unique strategies that these modulators of nucleosome structure use in malignant cells to circumvent the gauntlet of growth control mechanisms not only helps to elucidate the fascinating biology underlying chromatin regulation, but it also suggests that modulation of this system is useful in the clinic. First, aberrant expression of PcG-TrxG proteins, or the stem cell-associated transcriptional programmes that they regulate, could be used for cancer diagnosis. For example, the ability of BMI1 to cooperate with oncogenic HRAS leads to aggressive and highly metastatic tumours that colonize the brain or lung, therefore BMI1 levels can help to classify tumour subtypes 114 . Second, PcG-TrxG status can be used to predict survival or treatment outcome. For example, in breast tumours, the increased expression of EZH2 is an especially powerful indicator of poor prognosis when coupled with low expression of p57 KIP2 (one of the CKIs that is silenced by EZH2) 130 . High expression of EZH2 is also a predictor of poor response to therapies for prostate cancer 131 . Third, strategies that re-establish the PcG-TrxG balance could be useful in treating cancer. HDAC and DNMT inhibitors -anticancer treatments that are currently used in the clinic -effectively reverse H3K27me3, leading to the transcriptional activation of cell cycle regulators 130 . Development of new HDAC and DNMT inhibitors is likely to help in this regard. Importantly, the reversibility of PcG-mediated transcriptional repression has important implications for the feasibility of reactivating loci that have been silenced in cancer. Future work that provides insight into the mechanisms whereby PcG-TrxG-mediated pathways converge to regulate cancer should continue to provide new insights. 
